MK-0782

MK-0782 is an investigational small molecule selective cyclooxygenase-2 (COX-2) inhibitor developed by Merck Sharp & Dohme for the treatment of inflammatory conditions, specifically osteoarthritis and rheumatoid arthritis. It was designed to inhibit the COX-2 enzyme, which is responsible for the synthesis of pro-inflammatory prostaglandins, thereby providing analgesic and anti-inflammatory relief while potentially reducing the risk of gastrointestinal toxicity compared to non-selective NSAIDs. Clinical development included Phase 2 endoscopy studies (such as NCT00543465 and NCT00531011) that evaluated the incidence of gastric and duodenal ulcers when MK-0782 was administered alone or in combination with low-dose aspirin, comparing its safety profile to other COX-2 inhibitors like rofecoxib and celecoxib. The development program for MK-0782 was ultimately terminated.